Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOLIFE SOLUTIONS INCBLFS · Entity 4614 | Chief Revenue Officer | August 25, 2023 | August 29, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOLIFE SOLUTIONS INC
Report date August 25, 2023 · Filed August 29, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,097 |
Reported balance
After 2023-08-25 transaction · row 1
1 source rowRow 1 · 2023-08-25 · Sale · Disposed 347 · Balance 42,097 F1: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2023 Filed Aug 29, 2023 21:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 347 | $10.99 | $3,813.53 |
DisclosureSEC source: 0001628280-23-030917 · wk-form4_1693346070.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,097 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 20:49 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 108 | $12.38 | $1,337.04 |
DisclosureSEC source: 0001628280-23-029687 · wk-form4_1692218936.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,444 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 22:09 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 679 | $19.50 | $13,240.50 |
DisclosureSEC source: 0001628280-23-025784 · wk-form4_1690409364.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,552 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 07-17-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 21:10 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 331 | $22.79 | $7,543.49 |
DisclosureSEC source: 0001628280-23-024862 · wk-form4_1689282625.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,231 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 10-07-2019 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 337 | $23.21 | $7,821.77 |
DisclosureSEC source: 0001437749-23-016544 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,562 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 15, 2023 Filed May 18, 2023 01:53 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 75 | $18.71 | $1,403.25 |
DisclosureSEC source: 0001437749-23-015005 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,899 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 430 | $19.33 | $8,311.90 |
DisclosureSEC source: 0001437749-23-010842 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,062 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. F2 · kind: Adoption date of referenced 10b5-1(c) plan is: 7/17/2020 Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 23:28 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 215 | $21.05 | $4,525.75 |
DisclosureSEC source: 0001437749-23-010569 · primary_doc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,492 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 23:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 771 | $20.03 | $15,443.13 |
DisclosureSEC source: 0001437749-23-009875 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,707 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 06, 2023 Filed May 17, 2023 01:48 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 771 | $20.03 | $15,443.13 |
DisclosureSEC source: 0001437749-23-014862 · rdgdoc.xml · nonDerivative · entry 2 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,619 F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. F3 · balance_after: This reflects the total amount beneficially owned by the reporting person as of April 10, 2023. Subsequent Form 4's filed by the reporting person after April 10, 2023 do not currently reflect the vesting of the 2,912 shares. Read SEC document |
| March 31, 2023 Filed May 17, 2023 01:48 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionRestricted Stock Award · Derivative | 2,912 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-014862 · rdgdoc.xml · derivative · entry 3 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,912 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · derivative.expiration_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 31, 2023 Filed May 17, 2023 01:48 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 2,912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-014862 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 903 | $22.75 | $20,543.25 |
DisclosureSEC source: 0001437749-23-005442 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,478 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 09, 2023 Filed Feb 14, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 56 | $24.60 | $1,377.60 |
DisclosureSEC source: 0001437749-23-003206 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,381 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 23, 2023 Filed Jan 26, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,000 | $25.02 | $25,020.00 |
DisclosureSEC source: 0001437749-23-001797 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,437 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $25.02, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 19, 2023 Filed Jan 21, 2023 00:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 538 | $22.93 | $12,336.34 |
DisclosureSEC source: 0001437749-23-001484 · rdgdoc.xml · nonDerivative · entry 2 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,437 F3 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 18, 2023 Filed Jan 21, 2023 00:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,000 | $25.04 | $75,120.00 |
DisclosureSEC source: 0001437749-23-001484 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,975 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.10, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 258 | $21.94 | $5,660.52 |
DisclosureSEC source: 0001437749-23-000970 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,975 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 03, 2023 Filed Jan 11, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 12,733 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-000818 · rdgdoc.xml · derivative · entry 2 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,733 Underlying: Common Stock · 12,733 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| January 03, 2023 Filed Jan 11, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 12,733 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-000818 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,233 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 01:06 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 40 | $23.16 | $926.40 |
DisclosureSEC source: 0001437749-22-027398 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,500 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 400 | $21.76 | $8,704.00 |
DisclosureSEC source: 0001437749-22-025240 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,540 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 14, 2022 Filed Oct 19, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 236 | $21.80 | $5,144.80 |
DisclosureSEC source: 0001437749-22-024345 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,940 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 42 | $23.17 | $973.14 |
DisclosureSEC source: 0001437749-22-020215 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,176 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 03, 2022 Filed Aug 6, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,600 | $20.03 | $92,138.00 |
DisclosureSEC source: 0001437749-22-019237 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,218 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of June 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.06, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 22, 2022 Filed Jul 27, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 367 | $17.94 | $6,583.98 |
DisclosureSEC source: 0001437749-22-017813 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,818 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 12, 2022 Filed Jul 15, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 254 | $15.79 | $4,010.66 |
DisclosureSEC source: 0001437749-22-017162 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,185 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 13, 2022 Filed May 18, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 41 | $12.32 | $505.12 |
DisclosureSEC source: 0001437749-22-012846 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,439 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 21, 2022 Filed Apr 23, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 477 | $13.94 | $6,649.38 |
DisclosureSEC source: 0001437749-22-009566 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,480 F1 · kind: The sale reported herein was made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 00:15 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 286 | $17.59 | $5,030.74 |
DisclosureSEC source: 0001437749-22-009259 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,957 F1 · date: The sales reported herein were made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. The sales were made by the broker on April 13, 2022, April 14, 2022 and April 18, 2022. The high sales price during the period was $19.22, the low sales price during the period was $16.33 and the weighted average sales price was $17.59. F1 · kind: The sales reported herein were made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. The sales were made by the broker on April 13, 2022, April 14, 2022 and April 18, 2022. The high sales price during the period was $19.22, the low sales price during the period was $16.33 and the weighted average sales price was $17.59. F1 · price: The sales reported herein were made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. The sales were made by the broker on April 13, 2022, April 14, 2022 and April 18, 2022. The high sales price during the period was $19.22, the low sales price during the period was $16.33 and the weighted average sales price was $17.59. Read SEC document |
| February 24, 2022 Filed Mar 10, 2022 02:20 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 14,019 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-005771 · rdgdoc.xml · derivative · entry 2 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,019 Underlying: Common Stock · 14,019 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 24, 2022 Filed Mar 10, 2022 02:20 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 14,019 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-005771 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,243 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2022 compensation. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 01:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 167 | $29.38 | $4,906.46 |
DisclosureSEC source: 0001437749-22-003347 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,224 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 20, 2022 Filed Jan 25, 2022 02:07 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 395 | $30.24 | $11,944.80 |
DisclosureSEC source: 0001437749-22-001523 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,391 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 267 | $32.18 | $8,592.06 |
DisclosureSEC source: 0001437749-22-000889 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,786 F1 · shares: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 09, 2021 Filed Nov 13, 2021 01:21 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,750 | $53.00 | $92,750.00 |
DisclosureSEC source: 0001437749-21-026560 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,053 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of August 19, 2021. Read SEC document |
| October 20, 2021 Filed Oct 23, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 399 | $42.34 | $16,893.66 |
DisclosureSEC source: 0001437749-21-024188 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,803 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 11, 2021 Filed Oct 14, 2021 00:09 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 245 | $38.22 | $9,363.90 |
DisclosureSEC source: 0001437749-21-023621 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,202 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 26, 2021 Filed Jul 29, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 650 | $46.78 | $30,407.00 |
DisclosureSEC source: 0001437749-21-017792 · rdgdoc.xml · nonDerivative · entry 2 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,447 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. Read SEC document |
| July 26, 2021 Filed Jul 29, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,269 | $45.48 | $194,154.12 |
DisclosureSEC source: 0001437749-21-017792 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,097 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.76 to $46.42, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 20, 2021 Filed Jul 23, 2021 00:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,539 | $45.10 | $114,508.90 |
DisclosureSEC source: 0001437749-21-017395 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,366 F1 · shares: The sales reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 08, 2021 Filed Jul 10, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 140 | $45.72 | $6,400.80 |
DisclosureSEC source: 0001437749-21-016741 · rdgdoc.xml · nonDerivative · entry 2 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,905 F1 · shares: The sales reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 08, 2021 Filed Jul 10, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 100 | $45.75 | $4,575.00 |
DisclosureSEC source: 0001437749-21-016741 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,045 F1 · shares: The sales reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 650 | $32.10 | $20,865.00 |
DisclosureSEC source: 0001437749-21-009507 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,145 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. Read SEC document |
| April 08, 2021 Filed Apr 13, 2021 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 224 | $35.77 | $8,012.48 |
DisclosureSEC source: 0001437749-21-008758 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,795 F1 · shares: The sales reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.75 to $35.78, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 12, 2021 Filed Mar 6, 2021 01:01 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,000 | $41.01 | $82,020.00 |
DisclosureSEC source: 0001437749-21-005202 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,107 F1 · security: This Form 4/A is being filed to amend the Form 4 originally filed by the reporting person on February 16, 2021 solely to correct the transaction date in Column 2 on Table I. No other changes have been made to the original Form 4. F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 2,912 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-003515 · rdgdoc.xml · derivative · entry 2 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,912 Underlying: Common Stock · 2,912 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 2,912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003515 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,019 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation. Read SEC document |
| January 12, 2021 Filed Feb 17, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,000 | $41.01 | $82,020.00 |
DisclosureSEC source: 0001437749-21-003035 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Chief Revenue Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,107 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. Read SEC document |
| January 08, 2021 Filed Jan 14, 2021 01:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 293 | $39.01 | $11,429.93 |
DisclosureSEC source: 0001437749-21-000683 · rdgdoc.xml · nonDerivative · entry 1 Schulz Marcus · CIK 0001812702 · Vice President, Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,107 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.